
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Polycystic Ovary Syndrome Undergoes Name Change: Polyendocrine Metabolic Ovarian Syndrome
2
Amid Mounting Pressure, FDA Commissioner Marty Makary to Resign
3
GLP-1 Receptor Agonists Linked to Improved Survival Outcomes in Breast Cancer
4
From Misdiagnosis to Advocacy: Addressing Bias and Equity in Heart Failure Management
5


































































































































